Active, Not Recruiting
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- GSK Investigational Site Westwood, Kansas, United States
- GSK Investigational Site Charlotte, North Carolina, United States
- GSK Investigational Site Madison, Wisconsin, United States
- GSK Investigational Site Newcastle, New South Wales, Australia